Skip Ribbon Commands
Skip to main content
Sign In

26383 Acetylcholine Receptor Modulating Antibody (0099521)

Acetylcholine Receptor Modulating Antibody (0099521)
Test Code: ARMASO
Synonyms/Keywords

​​Acetylcholine Receptor Modulating Antibodies (0099521)

AChR Antibody

ACHR modulating antibody

Muscle nicotinic Acetylcholine Receptor (AChR) Modulating Antibody

Myasthenia Gravis Antibodies

Useful For

Assessment of clinical activity of and initial diagnostic testing for myasthenia gravis.

Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​No​Serum​Serum Separator Tube (SST)​0.5 mL​0.3 mL
Specimen Stability Information
Specimen TypeTemperatureTime
Serum​ ​ ​​Ambient​48 hours
​Refrigerated​14 days
​Frozen​1 year
Rejection Criteria

Gross hemolysis

Gross lipemia

Contaminated specimen

Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
ARUP Laboratories​​Sunday through Friday​2-7 days​Semi-Quantitative Flow Cytometry
Reference Lab
Reference Range Information
Performing LocationReference Range
ARUP Laboratories​

Negative 0-45% modulating

Interpretation

​Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

Reference Interval:  Negative 0-45% modulating; Positive 46% or greater modulating.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
86043​​​1
Synonyms/Keywords

​​Acetylcholine Receptor Modulating Antibodies (0099521)

AChR Antibody

ACHR modulating antibody

Muscle nicotinic Acetylcholine Receptor (AChR) Modulating Antibody

Myasthenia Gravis Antibodies

Ordering Applications
Ordering ApplicationDescription
​COM​Acetylcholine Receptor Mod Abs (0099521)
​Cerner​Acetylcholine Receptor Modulating Antibodies (0099521)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting RequiredSpecimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​No​Serum​Serum Separator Tube (SST)​0.5 mL​0.3 mL
Specimen Stability Information
Specimen TypeTemperatureTime
Serum​ ​ ​​Ambient​48 hours
​Refrigerated​14 days
​Frozen​1 year
Rejection Criteria

Gross hemolysis

Gross lipemia

Contaminated specimen

Useful For

Assessment of clinical activity of and initial diagnostic testing for myasthenia gravis.

Reference Range Information
Performing LocationReference Range
ARUP Laboratories​

Negative 0-45% modulating

Interpretation

​Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

Reference Interval:  Negative 0-45% modulating; Positive 46% or greater modulating.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
ARUP Laboratories​​Sunday through Friday​2-7 days​Semi-Quantitative Flow Cytometry
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
86043​​​1
For most current information refer to the Marshfield Laboratory online reference manual.